<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237831</url>
  </required_header>
  <id_info>
    <org_study_id>CV019-008</org_study_id>
    <nct_id>NCT04237831</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986259 in Participants With Varying Degrees of Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the drug effect, safety, and tolerability of BMS-986259 in participants&#xD;
      with different levels of kidney function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment temporarily on hold due to COVID-19&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Actual">July 16, 2021</completion_date>
  <primary_completion_date type="Actual">July 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serum</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration in plasma (Tmax) of BMS-986259 in blood serum</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration- time curve over the dosing interval of BMS-986259 in blood serum - AUC(TAU)</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of BMS-986259 in blood serum at 24 hours (C24)</measure>
    <time_frame>Day 1 and Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of BMS-986259 from time 0 (dosing) to the time of the last quantifiable - AUC(0-T)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio in the maximum plasma concentration of BMS-986259 in blood serum -AR(Cmax)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio of Area under the concentration-time curve in BMS-986259 over the dosing interval -AR (AUC [TAU])</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio concentration of BMS-986259 at 24 hours- AR(C24)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life of BMS-986259 (T-HALF)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total clearance of BMS-986259 at steady-state (CLss/F)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution of BMS-986259 at terminal phase at steady-state (Vss/F)</measure>
    <time_frame>Day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Non serious Adverse Events (AEs)</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in vital signs</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number in clinically significant changes in Electrocardiogram (ECG)</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in physical examinations</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>Arm A: Normal Renal Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Severe Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986259</intervention_name>
    <description>Specified Dose on Specified Days</description>
    <arm_group_label>Arm A: Normal Renal Function</arm_group_label>
    <arm_group_label>Arm B: Mild Renal Impairment</arm_group_label>
    <arm_group_label>Arm C: Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Arm D: Severe Renal Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have renal impairment, as defined by eGFR at screening using the&#xD;
             Chronic Kidney Disease Epidemiology (CKD-EPI) equation&#xD;
&#xD;
          -  No change in medications to control Chronic Kidney Disease (CKD) for at least 2 weeks&#xD;
             prior to dosing, and if possible, during confinement in the clinical research unit&#xD;
             (CRU), except those cleared by the investigator and Medical Monitor.&#xD;
&#xD;
          -  Participants with normal renal function at screening, based upon the opinion of the&#xD;
             investigator's medical evaluation.&#xD;
&#xD;
          -  Medically well-controlled disorders (eg, stable chronic asthma, allergy) are permitted&#xD;
             if the treatment for the disease does not interfere with the study.&#xD;
&#xD;
          -  Women and men must use highly effective methods of contraception for the duration of&#xD;
             treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any significant drug allergy or drug-related Serious Adverse Events (SAE)&#xD;
             (such as anaphylaxis or hepatotoxicity)&#xD;
&#xD;
          -  Positive results for drugs abuse in urine/saliva&#xD;
&#xD;
          -  Participants undergoing any method of dialysis (eg, hemodialysis, peritoneal dialysis)&#xD;
             within the last 3 months or with anticipated need for dialysis during the study&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECG, or clinical laboratory assessments beyond what&#xD;
             is consistent with the target population&#xD;
&#xD;
          -  Known previous exposure to BMS-986259&#xD;
&#xD;
        Other inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Clinical Research</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 19, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

